Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
OTCPK:ALIOF's Cash-to-Debt is ranked higher than
89% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OTCPK:ALIOF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:ALIOF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.3  Med: 3.78 Max: No Debt
Current: No Debt
Equity-to-Asset 0.63
OTCPK:ALIOF's Equity-to-Asset is ranked lower than
55% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OTCPK:ALIOF: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:ALIOF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.55 Max: 0.7
Current: 0.63
0.3
0.7
Interest Coverage 414.46
OTCPK:ALIOF's Interest Coverage is ranked lower than
67% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:ALIOF: 414.46 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:ALIOF' s Interest Coverage Range Over the Past 10 Years
Min: 0.3  Med: 57.05 Max: No Debt
Current: 414.46
Piotroski F-Score: 7
Altman Z-Score: 25.85
Beneish M-Score: -2.92
WACC vs ROIC
6.32%
76.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 32.62
OTCPK:ALIOF's Operating Margin % is ranked higher than
93% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. OTCPK:ALIOF: 32.62 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:ALIOF' s Operating Margin % Range Over the Past 10 Years
Min: 0.68  Med: 24.79 Max: 32.62
Current: 32.62
0.68
32.62
Net Margin % 28.80
OTCPK:ALIOF's Net Margin % is ranked higher than
92% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. OTCPK:ALIOF: 28.80 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:ALIOF' s Net Margin % Range Over the Past 10 Years
Min: -8.15  Med: 20.51 Max: 30.33
Current: 28.8
-8.15
30.33
ROE % 51.74
OTCPK:ALIOF's ROE % is ranked higher than
98% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. OTCPK:ALIOF: 51.74 )
Ranked among companies with meaningful ROE % only.
OTCPK:ALIOF' s ROE % Range Over the Past 10 Years
Min: -8.85  Med: 27.86 Max: 52.69
Current: 51.74
-8.85
52.69
ROA % 34.73
OTCPK:ALIOF's ROA % is ranked higher than
98% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OTCPK:ALIOF: 34.73 )
Ranked among companies with meaningful ROA % only.
OTCPK:ALIOF' s ROA % Range Over the Past 10 Years
Min: -5.18  Med: 14.9 Max: 34.73
Current: 34.73
-5.18
34.73
ROC (Joel Greenblatt) % 156.74
OTCPK:ALIOF's ROC (Joel Greenblatt) % is ranked higher than
95% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OTCPK:ALIOF: 156.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:ALIOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.55  Med: 117.89 Max: 163.6
Current: 156.74
-5.55
163.6
3-Year Revenue Growth Rate 13.20
OTCPK:ALIOF's 3-Year Revenue Growth Rate is ranked higher than
64% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. OTCPK:ALIOF: 13.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:ALIOF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.9  Med: 10.7 Max: 37.2
Current: 13.2
-0.9
37.2
3-Year EBITDA Growth Rate 19.20
OTCPK:ALIOF's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OTCPK:ALIOF: 19.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:ALIOF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.4  Med: 17.95 Max: 133.9
Current: 19.2
-48.4
133.9
3-Year EPS without NRI Growth Rate 18.10
OTCPK:ALIOF's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OTCPK:ALIOF: 18.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:ALIOF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 21.1 Max: 83.4
Current: 18.1
0.5
83.4
GuruFocus has detected 4 Warning Signs with Actelion Ltd $OTCPK:ALIOF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:ALIOF's 30-Y Financials

Financials (Next Earnings Date: 2017-07-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2833
Compare:NAS:VRTX, NAS:INCY, NAS:ALXN, OTCPK:GIKLY, OTCPK:UCBJY, NAS:BMRN, OTCPK:CSLLY, OTCPK:NVZMF, OTCPK:GMXAY, NAS:REGN, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:ALNY, NAS:BIVV, NAS:EXEL, NAS:UTHR, NAS:IONS, NAS:NBIX » details
Traded in other countries:ACT.Germany, ATLNE.Switzerland, 0RN5.UK,
Headquarter Location:Switzerland
Actelion Ltd is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for diseases with unmet medical needs.

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Ratios

vs
industry
vs
history
PE Ratio 42.91
ALIOF's PE Ratio is ranked lower than
67% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. ALIOF: 42.91 )
Ranked among companies with meaningful PE Ratio only.
ALIOF' s PE Ratio Range Over the Past 10 Years
Min: 11.02  Med: 19.98 Max: 44.12
Current: 42.91
11.02
44.12
Forward PE Ratio 35.59
ALIOF's Forward PE Ratio is ranked lower than
84% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. ALIOF: 35.59 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.91
ALIOF's PE Ratio without NRI is ranked lower than
67% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. ALIOF: 42.91 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALIOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.02  Med: 19.98 Max: 44.12
Current: 42.91
11.02
44.12
Price-to-Owner-Earnings 36.40
ALIOF's Price-to-Owner-Earnings is ranked lower than
53% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. ALIOF: 36.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALIOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.84  Med: 24.55 Max: 2686.36
Current: 36.4
12.84
2686.36
PB Ratio 21.57
ALIOF's PB Ratio is ranked lower than
94% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ALIOF: 21.57 )
Ranked among companies with meaningful PB Ratio only.
ALIOF' s PB Ratio Range Over the Past 10 Years
Min: 2.35  Med: 4.75 Max: 22.17
Current: 21.57
2.35
22.17
PS Ratio 12.36
ALIOF's PS Ratio is ranked lower than
51% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ALIOF: 12.36 )
Ranked among companies with meaningful PS Ratio only.
ALIOF' s PS Ratio Range Over the Past 10 Years
Min: 1.96  Med: 4.79 Max: 12.7
Current: 12.36
1.96
12.7
Price-to-Free-Cash-Flow 34.65
ALIOF's Price-to-Free-Cash-Flow is ranked lower than
62% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. ALIOF: 34.65 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALIOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.64  Med: 23.87 Max: 187.42
Current: 34.65
8.64
187.42
Price-to-Operating-Cash-Flow 32.48
ALIOF's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. ALIOF: 32.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALIOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.44  Med: 19.66 Max: 137.53
Current: 32.48
8.44
137.53
EV-to-EBIT 35.46
ALIOF's EV-to-EBIT is ranked higher than
75% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ALIOF: 35.46 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIOF' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.9  Med: 17.8 Max: 37.8
Current: 35.46
-108.9
37.8
EV-to-EBITDA 31.90
ALIOF's EV-to-EBITDA is ranked higher than
76% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ALIOF: 31.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALIOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.3  Med: 17.1 Max: 206.8
Current: 31.9
-77.3
206.8
PEG Ratio 0.73
ALIOF's PEG Ratio is ranked higher than
84% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. ALIOF: 0.73 )
Ranked among companies with meaningful PEG Ratio only.
ALIOF' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.34
Current: 0.73
0
1.34
Current Ratio 2.10
ALIOF's Current Ratio is ranked lower than
73% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ALIOF: 2.10 )
Ranked among companies with meaningful Current Ratio only.
ALIOF' s Current Ratio Range Over the Past 10 Years
Min: 1.41  Med: 2.12 Max: 3.76
Current: 2.1
1.41
3.76
Quick Ratio 1.86
ALIOF's Quick Ratio is ranked lower than
71% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ALIOF: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
ALIOF' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.06 Max: 3.64
Current: 1.86
1.36
3.64
Days Inventory 159.91
ALIOF's Days Inventory is ranked lower than
61% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ALIOF: 159.91 )
Ranked among companies with meaningful Days Inventory only.
ALIOF' s Days Inventory Range Over the Past 10 Years
Min: 88.91  Med: 106.4 Max: 159.91
Current: 159.91
88.91
159.91

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.54
ALIOF's Dividend Yield % is ranked lower than
80% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. ALIOF: 0.54 )
Ranked among companies with meaningful Dividend Yield % only.
ALIOF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.53  Med: 1.15 Max: 2.7
Current: 0.54
0.53
2.7
Dividend Payout Ratio 0.23
ALIOF's Dividend Payout Ratio is ranked higher than
69% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. ALIOF: 0.23 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALIOF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.23  Med: 0.26 Max: 0.31
Current: 0.23
0.23
0.31
3-Year Dividend Growth Rate 14.50
ALIOF's 3-Year Dividend Growth Rate is ranked higher than
67% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. ALIOF: 14.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ALIOF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 17.6
Current: 14.5
0
17.6
5-Year Yield-on-Cost % 1.07
ALIOF's 5-Year Yield-on-Cost % is ranked lower than
63% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. ALIOF: 1.07 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALIOF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.05  Med: 2.27 Max: 5.34
Current: 1.07
1.05
5.34
3-Year Average Share Buyback Ratio 2.50
ALIOF's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ALIOF: 2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALIOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.7  Med: 1.6 Max: 2.5
Current: 2.5
-2.7
2.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 69.52
ALIOF's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ALIOF: 69.52 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALIOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.97  Med: 14.25 Max: 69.52
Current: 69.52
4.97
69.52
Price-to-Tangible-Book 35.41
ALIOF's Price-to-Tangible-Book is ranked lower than
95% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ALIOF: 35.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALIOF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.07  Med: 9.53 Max: 35.41
Current: 35.41
3.07
35.41
Price-to-Intrinsic-Value-Projected-FCF 4.64
ALIOF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. ALIOF: 4.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALIOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.01  Med: 3.04 Max: 4.64
Current: 4.64
2.01
4.64
Price-to-Median-PS-Value 2.58
ALIOF's Price-to-Median-PS-Value is ranked lower than
85% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALIOF: 2.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALIOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45  Med: 1.16 Max: 2.58
Current: 2.58
0.45
2.58
Price-to-Graham-Number 8.22
ALIOF's Price-to-Graham-Number is ranked lower than
88% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. ALIOF: 8.22 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALIOF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.7  Med: 3.31 Max: 8.44
Current: 8.22
1.7
8.44
Earnings Yield (Greenblatt) % 2.82
ALIOF's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ALIOF: 2.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALIOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 5.2 Max: 12.1
Current: 2.82
2.6
12.1

More Statistics

Revenue (TTM) (Mil) $2,453
EPS (TTM) $ 6.58
Beta1.79
Short Percentage of Float0.00%
52-Week Range $138.01 - 286.30
Shares Outstanding (Mil)102.69

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,368 2,496 2,596
EPS ($) 7.85 6.55 6.85
EPS without NRI ($) 7.85 6.55 6.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.37%
Dividends per Share ($) 1.49
» More Articles for OTCPK:ALIOF

Headlines

Articles On GuruFocus.com
Johnson & Johnson: Modest Price Decline Presents Buying Opportunity Apr 21 2017 
Johnson & Johnson Beats on Profit, Misses on Sales in 1st Quarter Apr 19 2017 
Johnson & Johnson Publishes Interim Result for Actelion Tender Offer and Declares the Tender Offer S Mar 31 2017 
Health Care Dividend Stock Showdown Mar 03 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
Jean Hynes Reduces Stake in Actelion Aug 03 2016 
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Johnson & Johnson offers EU concessions over Actelion deal May 18 2017
Actelion Ltd. – Value Analysis (US OTC:ALIOF) : May 2, 2017 May 02 2017
Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : May 1, 2017 May 01 2017
Here's Why Risk-Averse Investors May Want to Think Twice About Buying Johnson & Johnson Apr 25 2017
Were Johnson & Johnson's Earnings Really That Bad? Apr 24 2017
3 Things Johnson & Johnson Didn't Tell You in Its Q1 Earnings Update Apr 21 2017
J&J target Actelion could exit Swiss benchmark SMI index this month Apr 20 2017
[$$] Johnson & Johnson Lifts Forecast on Actelion Tie-Up Apr 18 2017
J&J first quarter revenue misses estimates; new forecast includes Actelion Apr 18 2017
Johnson & Johnson: Help Me Actelion, You're My Only Hope Apr 18 2017
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down Apr 18 2017
Johnson & Johnson Posts Sluggish Sales, Boosts Guidance on Actelion Deal Apr 18 2017
5 Things You Should Expect When Johnson & Johnson Reports Its Q1 Results Tomorrow Apr 17 2017
EMA gives green light to Actelion's Uptravi after safety review Apr 07 2017
[$$] Johnson & Johnson Set for Earnings Upside Apr 07 2017
Actelion shareholders back R&D spinoff, keep J&J deal on track Apr 05 2017
JNJ Declares Success of Actelion Tender, Sees Closing in Second Quarter Mar 31 2017
J&J declares Actelion tender offer a success, sees closing in second quarter Mar 31 2017
3 Drugmakers With Boatloads of Cash to Spend Mar 29 2017
4 Stocks That Will Likely Be Around in 50 Years Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)